Cargando…

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours

BACKGROUND: This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of two dosing schedules of oral topotecan in combination with pazopanib in patients with advanced solid tumours. METHODS: Stage I of this study was to determine whether there was an i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerklaan, B Milojkovic, Lolkema, M P J, Devriese, L A, Voest, E E, Nol-Boekel, A, Mergui-Roelvink, M, Langenberg, M, Mykulowycz, K, Stoebenau, J, Lane, S, Legenne, P, Wissel, P, Smith, D A, Giantonio, B J, Schellens, J H M, Witteveen, P O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559826/ https://www.ncbi.nlm.nih.gov/pubmed/26291057 http://dx.doi.org/10.1038/bjc.2015.257

Ejemplares similares

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
por: Cirkel, Geert A., et al.
Publicado: (2016)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review
por: Walraven, Maudy, et al.
Publicado: (2010)

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
por: Verheijen, R. B., et al.
Publicado: (2017)

Tracking the cell cycle origins for escape from topotecan action by breast cancer cells
por: Feeney, G P, et al.
Publicado: (2003)

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Carboplatin +/− Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma
por: Francis, Jasmine H., et al.
Publicado: (2013)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis
por: Léger, F, et al.
Publicado: (2004)

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)
por: Chekerov, Radoslav, et al.
Publicado: (2023)

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo
por: Chernyshova, Irina A., et al.
Publicado: (2022)

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies
por: Tan, A R, et al.
Publicado: (2014)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model
por: Kuehl, Philip J., et al.
Publicado: (2018)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
por: Attia, Steven, et al.
Publicado: (2015)

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
por: Fauster, A, et al.
Publicado: (2015)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study
por: Hamberg, P, et al.
Publicado: (2014)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
por: Poveda, A., et al.
Publicado: (2017)

A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer
por: Neuhaus, T, et al.
Publicado: (2009)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4nt8ok99f2jdgr668pqv7pmdpm